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ABSTRACT
Purpose 
The objectives of this study were to evaluate the effectiveness of nab-paclitaxel 
plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients 
with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the 
prognostic factors influencing overall survival (OS).
Experimental design 
Patients with age < 85 years, ECOG-performance status (PS) < 3, and adequate 
renal, hepatic and hematologic function were eligible. NAB-P (125 mg/m2) and GEM 
(1000 mg/m2) day 1,8,15 every 4 weeks were employed for 3–6 cycles or until 
highest response.
Results 
Overall, 147 cycles (median 4, range 1–11 cycles) were administered on thirty-
seven consecutive patients (median 66 years old, range 40–82) treated. The median 
overall progression-free survival and OS were 6.2 and 9.2 months, respectively. The 
G 3–4 dose-limiting toxicity were neutropenia (20.7%), severe anemia (17.2%), and 
cardiovascular toxicity (10.3%). PS, number of cycles, baseline CA 19–9 and LDH 
serum levels, were found to be significantly related to OS. The multivariate analysis 
showed that both number of cycles (HR = 9.14, 95% CI 1.84–45.50, p = 0.001) and 
PS (HR = 13.18, 95% CI 2.73–63.71, p = 0.001) were independently associated 
with OS.
Conclusion 
NAB-P/GEM regimen should be used in all patients with advanced or metastatic 
PC, with the exception of those with serious contraindications to chemotherapy, such 
as severe renal or hepatic impairment or major cardiovascular diseases.
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INTRODUCION
Pancreatic cancer (PC) is an aggressive tumor that 
accounts for approximately 3% of all cancers, whose 
incidence is increasing [1]. It represents the fourth 
leading cause of cancer death in the United States in 
both gender. PC remains a chemoresistant malignancy 
and the nucleoside analogue gemcitabine, which has 
represented for years the standard first-line therapy for 
patients with PC, provides limited clinical benefits, 
especially in advanced or metastatic disease [2, 3]. The 
prognosis of patients with PC is poor and their 5-year 
overall survival (OS) rate is only 5%, as approximately 
80% of patients are diagnosed when the disease has 
already given regional or distant metastases [1, 4]. 
Several alternative drugs have been tested, alone or in 
combination with gemcitabine, including oxaliplatin, 
capecitabine, cisplatin, 5-fluorouracil (5FU), erlotinib 
and bevacizumab, but none has significantly improved 
OS [5–10].
Two four-drug regimens, named PEFG (cisplatin, 
epirubicin, fluorouracil, gemcitabine) and FOLFIRINOX 
(folinic acid, 5FU, irinotecan, oxaliplatin), have been 
shown to give better results towards gemcitabine alone 
[11, 12]. More recently, a multicentric study comparing 
nab-paclitaxel (nanoparticle albumin-bound paclitaxel) 
plus gemcitabine (NAB-P/GEM) versus gemcitabine 
alone, reported significant survival benefit (1-year OS 
rate 35% vs. 22%) of this new regimen, offering another 
possibility in the management of patents with PC [13]. 
However, the exclusion criteria adopted in the selection 
of patients (i.e., Karnofsky performance-status score < 70 
on a scale from zero to 100, no previous chemotherapy 
for metastatic disease), restrict the use of this treatment 
protocol.
The purposes of the present study were (i) to 
evaluate the effectiveness of NAB-P/GEM regimen 
in an unselected population of patients with advanced 
inoperable or metastatic PC and (ii) to identify the 
prognostic factors influencing OS.
RESULTS
Patient characteristics
A series of 37 consecutive patients (20 males, 
17 females; median 66 years old, range 40–82) with 
locally advanced unresectable primary tumor (N = 6, 
16.2%) or metastatic (N = 31, 83.8%) PC were enrolled in 
the study. The local institutional ethics committee obtained 
written informed consent from all participants before 
therapy started and the study had full ethical approval. All 
patients were evaluated according to Eastern Cooperative 
Oncology Group performance status (ECOG-PS) protocol 
that uses a scale from 0 to 5, with higher score indicating 
illness or a very poor PS [14].
Patients underwent baseline standard hematological 
check-up, including complete blood cell count, bilirubin, 
creatinine, alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), lactate dehydrogenase (LDH), which 
were assayed using laboratory routine methods. Serum 
carbohydrate antigen (CA) 19–9 was measured using 
a commercially available immunoassay by automated 
heterogeneous chemiluminescent immunoassays that use 
N-(aminobutyl)-N-(ethylisoluminol) as luminescence 
substrate (Maglumi, Shenzen New Industries Biomedical 
Engineering, SNIBE, Shenzen, China).
Overall, the median baseline CA 19–9 level was 1734 
U/mL (range 2–120,000 U/mL), while the median values of 
hemoglobin, white blood cells (WBC), ALP and LDH were 
12 g/dL, 7230/μL, 136 U/L and 205 U/L, respectively.
Toxicity and antitumor activity
We obtained complete response in three (10.3%) 
and partial response in four (13.8%) out of 29 evaluable 
patients, whilst 16 (55.2%) and six (20.7%) patients 
had stable disease or progressive disease, respectively. 
The overall objective response rate and disease control 
rate were 19% (95% CI, 8%–30%) and 62% (95% CI, 
55%–69%), respectively, and the median duration of 
response was 8 months (range 1–9 months). The median 
overall progression-free survival (PFS) and OS were 6.2 
and 9.2 months, respectively (Figure 1A–1B). The grade 
(G) 3–4 dose-limiting toxicity were neutropenia in six 
(20.7%), severe anemia in five (17.2%), thrombocytopenia 
in two (6.9%), signs and symptoms of neurological 
and cardiovascular toxicity in three (10.3%) and one 
(3.4%) patients, respectively. One more patient (3.4%) 
complained of fatigue. Eight (21.6%) patients were not 
evaluable for early suspension.
The results of the univariate analysis are shown 
in Table 1. ECOG-PS (0–1 vs. 2), number of cycles 
(< 4 vs. ≥ 4), baseline CA 19–9 (< 1734 vs. ≥ 1734 U/
mL) and LDH (< 204 vs. ≥ 204 U/L) serum levels, were 
found to be significantly related to OS (Figure 2A–2D). The 
multivariate analysis showed that both number of cycles 
(HR = 9.14, 95% CI 1.84–45.50, p = 0.001 for < 4 vs. ≥ 
4 cycles) and PS (HR = 13.18, 95% CI 2.73–63.71, 
p = 0.001 for 2 vs. 0–1 ECOG-PS) were independently 
associated with OS.
DISCUSSION
Pancreatic cancer remains a very serious disease, 
characterized by a poor prognosis, for which a multidrug 
therapy is usually more effective than monotherapy. In a 
group of patients with PC who underwent FOLFIRINOX 
regimen versus gemcitabine alone, the median OS 
was 11.1 vs. 6.8 months (HR = 0.57, p < 0.001) and 
the median PFS was 6.4 vs. 3.3 months (HR = 0.47, 
p < 0.001) compared to the control group [12, 15]. 
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Figure 1: Overall survival. (A) and progression-free survival (B) of the overall population.
Table 1: Association between selected prognostic factors and overall survival. The hazard ratio (HR) 
is adjusted for all factors statistically significant in Kaplan-Meier analysis.
Parameter Median OS (months) Log-rank p HR 95% CI p
Age: 0.48 0.49 - -
< 66 years 10.5
≥ 66 years 9.0
Gender: 0.13 0.72 - -
Male 10.8
Female 9.2
ECOG-PS 23.66 < 0.001
0–1 11.3 1 2.73–63.71 0.001
2 3.4 13.18
No. of cycles 17.79 < 0.001
≥ 4 11.3 1 1.84–45.50 0.001
< 4 3.4 9.14
Hemoglobin 0.09 0.76 - -
< 12 g/dL 9.0
≥ 12 g/dL 10.5
WBC 0.09 0.76 - -
< 7230/μL 9.2
≥ 7230/μL 10.8
ALP 0.27 1.24 - -
< 136 U/L 10.5
≥ 136 U/L 7.1
LDH 4.16 0.04
< 204 U/L 10.8 1 0.27–4.41 0.91
≥ 204 U/L 5.3 1.09
CA 19–9 4.59 0.03
< 1734 U/mL 10.8 1 0.29–3.35 0.99
≥ 1734 U/mL 7.1 0.99
OS, overall survival; p, p-value; HR, hazard ratio; 95% CI, 95% confidence interval; ECOG-PS, Eastern Cooperative 
Oncology Group performance status; WBC, white blood cells; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; 
carbohydrate antigen (CA) 19–9.
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Unfortunately, FOLFIRINOX increases gastrointestinal 
and neurosensorial toxicity, thus reducing the quality of 
life parameters compared to gemcitabine regimen alone in 
patients with metastatic PC [15]. Moreover, the exclusion 
criteria of FOLFIRINOX protocol, such as age ≥ 76 years, 
ECOG-PS ≥ 2, and site of primary tumor, may partially 
justify the longer OS, thus limiting its use in unselected 
population of patients with PC [16].
Another effective regimen is NAB-P/GEM that 
demonstrates superiority on response rate and PFS over 
gemcitabine [13]. Nab-paclitaxel was initially developed 
to avoid hypersensitivity phenomena related to solvents 
such as polyethylated castor oil (Cremophor EL, BASF, 
Ludwigshafen, Germany) used as vehicle [17]. In PC with 
dense stroma and high levels of secreting protein acidic 
and rich in cysteine, the efficacy of NAB-P is higher 
because the albumin-binding protein sequestrates NAB-P, 
which concentrates within the tumor tissue [18]. It also 
synergize with gemcitabine, which increases by 2.8 times 
the intratumoral concentration of the drug [19]. NAB-P/
GEM should also be considered as salvage therapy after 
ineffective first-line FOLFIRINOX treatment [20].
Using The Quality-Adjusted Time Without 
Symptoms or Toxicities (Q-TWiST) methodology it has 
been shown that patients treated with NAB-P/GEM have 
a significant gain in the quality-adjusted survival, when 
compared to those treated with gemcitabine alone [21]. 
A meta-analysis on studies of patients with metastatic PC 
treated with single-agent or combination chemotherapy 
regimens, including NAB-P/GEM and FOLFIRINOX, 
showed the superiority of multidrug protocols versus 
gemcitabine alone and the substantial equivalence between 
NAB-P/GEM and FOLFIRINOX [4]. Another review 
confirmed that both regimens should be considered the 
treatment of choice as first-line chemotherapy in patients 
with metastatic PC [22]. The results of our study confirm 
the effectiveness of the protocol NAB-P/GEM (PFS = 
6.2 months, OS = 9.2 months) also in a population of 
unselected patients with advanced or metastatic PC, and 
the multivariate analysis showed that both PS and number 
of cycles of therapy were independently associated with 
OS. This suggests that even patients with PS < 2 may 
tolerate a high number of cycles of therapy, which could 
enable them to prolong OS.
Figure 2: Overall survival according to Eastern Cooperative Oncology Group performance status (PS). (A) number of 
cycles (B) baseline carbohydrate antigen (CA) 19–9 (C) and lactate dehydrogenase (LDH) (D) serum levels.
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METHODS
Patient selection
Inclusion criteria were the following: (i) age 
< 85 years, (ii) ECOG-PS < 3, (iii) histological diagnosis 
of pancreatic non-neuroendocrine adenocarcinoma, 
(iv) metastatic PC on 18F-2-deoxy-fluoro-D-glucose (FDG) 
positron-emission tomography/computed tomography 
(PET/CT) or locally advanced unresectable primary tumor 
on contrast-enhanced CT scan, (v) adequate renal, hepatic 
and hematologic function, including serum creatinine 
< 1.5 mg/dL, ALT < 2 times upper the limit of the normal 
range, hemoglobin ≥ 9 g/dL, WBC > 4000/μL, and 
absolute neutrophil count > 1500/μL. Patients who had 
received adjuvant or palliative chemotherapy or radiation 
therapy more than 6 weeks before the start of the study, 
were also included.
Exclusion criteria were limited to serious 
cardiovascular problems (i.e., heart failure, instable 
angina, ventricular arrhythmia, ejection fraction < 50%), 
presence of obstructive jaundice or recent replacement of 
infected biliary stenting.
There were 29 (78.4%) treatment-naive patients and 
8 (21.6%) previously treated patients. Sites of metastases 
on PET/CT were liver (N = 21 out of 31, 67.7%), pancreas 
(N = 19, 61.3%), peritoneum (N = 13, 41.9%), regional 
lymph nodes (N = 10, 32.3%), lung (N = 6, 19.4%) or 
other sites (N = 3, 9.7%).
Procedures
NAB-P (125 mg/m2) and GEM (1000 mg/m2) 
were administered on day 1, 8, 15 every 28 days for 
at least 3 cycles. A dose reduction of 25% for patient 
with ECOG-PS = 2 was planned at the beginning of 
treatment, followed by dose increase if good tolerance 
and PS improvement appeared. In the presence of stable 
disease or objective response detected on CT scan, the 
treatment continued until 6–7 cycles. In presence of 
G 3–4 neutropenia, after recovery of toxicity, a secondary 
prophylaxis with granulocyte-colony stimulating factor 
(G-CSF) was employed in the next cycles. In patients 
with a higher degree of toxicity (G > 4), recovery to 
G ≤ 1 before continuing therapy was required. Overall, 147 
cycles (median 4, range 1–11 cycles) were administered.
Statistical analysis
Survival probabilities were estimated by means of 
the Kaplan-Meier method and compared, at univariate 
analysis, using the log-rank test. Parameters with a 
statistically significant log-rank test were considered 
independent variables and included in the multivariate 
Cox proportional hazard regression linear model 
to compare hazard ratio (HR) and 95% confidence 
interval (95% CI). A two-sided p-value < 0.05 was 
considered statistically significant. SAS version 9.20 
(SAS Institute Inc., Cary, NC, USA, 2002–2008) was 
used for statistical analysis.
CONCLUSION
NAB-P/GEM should be used in all patients with 
advanced or metastatic PC, with the exception of those with 
serious contraindications to chemotherapy, such as renal or 
hepatic impairment or major cardiovascular diseases. Future 
studies, performed on less selected patient populations, are 
required to confirm these preliminary outcomes.
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